KLRS Announces CFO Matthew Gall Resignation Effective April 14 2026 Brett Hagen Becomes Principal Financial Officer
Kalaris Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $4.90
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS